EP Patent

EP1488805A2 — CD28 pathway immunoregulation

Assigned to University of Michigan System · Expires 2004-12-22 · 21y expired

What this patent protects

Use of an anti-CD28 antibody or a F(ab') 2 fragment thereof in the manufacture of a medicament for administration to a population of CD3-activated CD28 + T-cells of a patient to promote the production of a cyclosporine resistant lymphokine selected from IL-2, TNF, IFN-gamma…

USPTO Abstract

Use of an anti-CD28 antibody or a F(ab') 2 fragment thereof in the manufacture of a medicament for administration to a population of CD3-activated CD28 + T-cells of a patient to promote the production of a cyclosporine resistant lymphokine selected from IL-2, TNF, IFN-gamma and GM-CSF.

Drugs covered by this patent

Patent Metadata

Patent number
EP1488805A2
Jurisdiction
EP
Classification
—
Expires
2004-12-22
Drug substance claim
No
Drug product claim
No
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.